Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

428.86 +2.10 (+0.49%)

Streaming Delayed Price Updated: 10:05 AM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

68 69 Next >

2 Healthcare Growth Stocks That Are No-Brainer Buys Right Now ↗

February 17, 2024

The healthcare industry often remains resilient amid macro headwinds, and these two stocks are prime examples.

Via The Motley Fool

Giving Uber Its Due ↗

February 15, 2024

We've also got a look at good news from Chipotle and Roblox, and we put some stocks on a dating show.

Via The Motley Fool

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade. ↗

February 15, 2024

These stocks have what it takes to drive superior returns in the years to come.

Via The Motley Fool

Gene therapy: Why does it cost millions for a single treatment?

February 15, 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.

Via MarketBeat

Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x? ↗

February 15, 2024

There's more to consider with Vertex's valuation than one number.

Via The Motley Fool

Stock-Split Watch: Is Vertex Pharmaceuticals Next? ↗

February 14, 2024

It's on track to launch more blockbuster drugs.

Via The Motley Fool

Could Vertex Pharmaceuticals Reach $500 in 2024? ↗

February 10, 2024

Vertex shares have several catalysts on the horizon...

Via The Motley Fool

Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy? ↗

February 08, 2024

Its pain medicine isn't precisely what it hoped for, but it could still sell.

Via The Motley Fool

If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today ↗

February 13, 2024

You can't go back in the past, but it's not too late to invest in this top stock.

Via The Motley Fool

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

February 13, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Healthcare Stocks That Could Help Set You Up for Life ↗

February 12, 2024

These rock-solid businesses can add meaningful returns to a long-term portfolio.

Via The Motley Fool

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains ↗

February 11, 2024

Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector.

Via InvestorPlace

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

February 07, 2024

Via Benzinga

This High-Flying Stock Just Got Some Bad News: Should You Sell? ↗

February 06, 2024

It's just a minor setback for this leading biotech.

Via The Motley Fool

Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat ↗

February 05, 2024

The company also topped fourth-quarter expectations.

Via Investor's Business Daily

Is Vertex Pharmaceuticals Stock a Buy Now? ↗

February 10, 2024

The company just released its latest earnings report, and growth investors may be a little disappointed.

Via The Motley Fool

2 Healthcare Stocks You Can Buy and Hold for the Next Decade ↗

February 10, 2024

These businesses are built to last.

Via The Motley Fool

2 No-Brainer Healthcare Stocks to Buy Right Now ↗

February 10, 2024

Companies in the healthcare industry tend to generate returns in a wide range of market environments.

Via The Motley Fool

3 Stocks That Could Trounce the Market in 2024 ↗

February 10, 2024

These stocks appear to have what it takes to beat the market this year.

Via The Motley Fool

3 Growth Stocks With More Potential Than Any Cryptocurrency ↗

February 09, 2024

The stock market is full of opportunities for investors of all risk appetites and trading styles.

Via The Motley Fool

3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List ↗

February 09, 2024

These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why.

Via InvestorPlace

Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review ↗

February 08, 2024

The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply.

Via Investor's Business Daily

Topics Artificial Intelligence Stocks

Vertex's Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs ↗

February 06, 2024

Vertex Pharmaceuticals' cystic fibrosis treatment with vanza triple therapy. SKYLINE trials show non-inferiority to Trikafta, emphasizing once-daily dosing benefits.

Via Benzinga

Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients ↗

February 06, 2024

Vertex Pharmaceuticals' vanza triple program for cystic fibrosis, with superior results in lung function, sweat chloride reduction, and safety.

Via Benzinga

Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest ↗

February 06, 2024

Its foray into developing analgesics seems to be going swimmingly.

Via The Motley Fool

Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 06, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024 ↗

February 06, 2024

Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements.

Via InvestorPlace

Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript ↗

February 05, 2024

VRTX earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Vertex Reports Fourth Quarter and Full Year 2023 Financial Results

February 05, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis

February 05, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.